Immunotherapy for Peritoneal Metastases from Gastric Cancer: Rationale, Current Practice and Ongoing Trials
Peritoneal metastases from gastric cancer play a key role in the fatal prognosis of the disease. The lack of efficacy of actual therapeutic approaches together with the outcomes achieved with checkpoint inhibitors in gastric cancer compel us to address the current state-of-the-art immunotherapy trea...
Main Authors: | Eva Ruiz Hispán, Manuel Pedregal, Ion Cristobal, Jesús García-Foncillas, Cristina Caramés |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-10-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/20/4649 |
Similar Items
-
The Role of CAR-T Cells in Peritoneal Carcinomatosis from Gastric Cancer: Rationale, Experimental Work, and Clinical Applications
by: Siyuan Qian, et al.
Published: (2021-10-01) -
Treatment of peritoneal metastases from gastric carcinoma
by: Polkowski Wojciech P., et al.
Published: (2017-12-01) -
HIPEC in Peritoneal Metastasis of Gastric Origin: A Systematic Review of Regimens and Techniques
by: Felix Gronau, et al.
Published: (2022-03-01) -
Review of Regional Therapies for Gastric Cancer with Peritoneal Metastases
by: Beatrice J. Sun, et al.
Published: (2022-01-01) -
Peritoneal Metastatic Gastric Cancer: Local Treatment Options and Recommendations
by: Miklos Acs, et al.
Published: (2024-03-01)